

GUSTAFSSON, David
Appl. No. 09/582,863
October 3, 2003



AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-19 (cancelled).

RECEIVED

OCT 15 2003

CL
20 (previously presented). A kit of parts comprising:

TECH CENTER 1600/2900

(a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and

(b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

21 (currently amended). AThe kit of parts as claimed in Claim 20, wherein the prodrug of component (b) is a prodrug of the thrombin inhibitor of component (a).


22. (currently amended). AThe kit of parts as claimed in Claim 20, wherein components (a) and (b) are suitable for sequential, separate or simultaneous use in the treatment of a condition in which inhibition of thrombin is required or desired.

23 (currently amended). AThe kit of parts as claimed in Claim 22, wherein the

condition is deep venous thrombosis.

24 (currently amended). -A-The kit of parts as claimed in Claim 20, wherein the thrombin inhibitor is melagatran.

*Cl
cont.* 25 (currently amended). -A-The kit of parts as claimed in Claim 24, wherein the prodrug is of the formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the 'OH group replaces one of the amidino hydrogens in Pab.

26 (currently amended). -A-The kit of parts as claimed in Claim 25, wherein R^1 represents methyl, ethyl or propyl.

27 (currently amended). -A-The kit of parts as claimed in Claim 25, wherein R^1 represents ethyl.

28 (currently amended). -A-The kit of parts as claimed in Claim 20, 21, 24 or 27, wherein the formulation comprising thrombin inhibitor, or derivative thereof, is a parenteral formulation and that comprising the prodrug, or derivative thereof, is an oral formulation.

29 (currently amended). A method of making ~~a~~the kit of parts as defined in Claim 20, 21, 24 or 27, which method comprises bringing a component (a) into association with a component (b), thus rendering the two components suitable for administration in conjunction with each other.

*C1
Cont.*

30 (currently amended). ~~A~~The kit of parts comprising:

- (1) one of components (a) and (b) as defined in Claim 20, 21, 24 or 27; together with
- (2) instructions to use that component in conjunction with the other of the two components.

31 (previously presented). A pharmaceutical formulation including a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative thereof) and a prodrug of a low molecular weight thrombin inhibitor (or a pharmaceutically acceptable derivative of that prodrug), in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

32 (currently amended). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of:

- (a) a pharmaceutical formulation including a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction

with

(b) a pharmaceutical formulation including a prodrug of a low molecular weight thrombin inhibitor, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier, to a patient suffering from, or susceptible to, such a condition in an effective amount and for a time and under conditions suitable for reducing the incidence of said condition.

*Cl
Cmt.* 33 (currently amended). A The method as claimed in Claim 32 in which component formulation (a) is administered prior to commencement of administration of component formulation (b).

34 (currently amended). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of a formulation as defined in Claim 31 to a patient suffering from, or susceptible to, such a condition in an effective amount and for a time and under conditions suitable for reducing the incidence of said condition.

35 (currently amended). A The method as claimed in Claim 32, wherein the condition is deep venous thrombosis.

36 (currently amended). A The method as claimed in Claim 35, wherein the thrombosis results from surgery.

37 (currently amended). A The method as claimed in Claim 36, wherein the surgery is gastrointestinal surgery or orthopedic surgery.

38 (currently amended). A The method as claimed in Claim 36, wherein component formulation (a) is administered parenterally prior to or after surgery and component formulation (b) is administered orally following that surgery.


Claim
39 (currently amended). A The method as claimed in Claim 36, wherein component formulation (a) is administered parenterally prior to and after surgery and component formulation (b) is administered orally following that surgery.

40 (currently amended). A The method as claimed in Claim 32, 35, 36, 37, 38 or 39, wherein the thrombin inhibitor is melagatran.

41 (currently amended). A method of treatment of a condition in which inhibition of thrombin is required or desired, which comprises administration of:

(a) a pharmaceutical formulation including melagatran, or a pharmaceutically acceptable derivative thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; in conjunction with

(b) a pharmaceutical formulation including a prodrug of formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces

one of the amidino hydrogens in Pab, or a pharmaceutically acceptable derivative of that prodrug, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier,

to a patient suffering from, or susceptible to, such a condition in an effective amount and for a time and under conditions suitable for reducing the incidence of said condition.

*C1
cont.* 42 (currently amended). A The method as claimed in Claim 41, wherein R¹ represents methyl, ethyl or propyl.


43 (currently amended). A The method as claimed in Claim 41, wherein R¹ represents ethyl.

44 (currently amended). A The method as claimed in Claim 32 wherein the prodrug of component formulation (b) is a prodrug of the thrombin inhibitor of component formulation (a).

45 (currently amended). A The pharmaceutical formulation as claimed in Claim 31 wherein the prodrug is a prodrug of the thrombin inhibitor.

46 (currently amended). A The pharmaceutical formulation as claimed in Claim 31 wherein the thrombin inhibitor is melagatran.

47 (currently amended). A The pharmaceutical formulation as claimed in Claim
46 wherein the prodrug is of the formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces
one of the amidino hydrogens in Pab.

*Ch
cont.*
48 (currently amended). A The pharmaceutical formulation as claimed in Claim
47 wherein R^1 represents methyl, ethyl, or propyl.

49 (currently amended). A The pharmaceutical formulation as claimed in Claim
47 wherein R^1 represents ethyl.

50 (currently amended). A The method as claimed in claimed 34 wherein the
prodrug is a prodrug of the thrombin inhibitor.

51 (currently amended). A The method as claimed in Claim 34 wherein the
condition is deep venous thrombosis.


52 (currently amended). A The method as claimed in Claim 51 wherein the
thrombosis results from surgery.

GUSTAFSSON, David
Appl. No. 09/582,863
October 3, 2003

53 (currently amended). A The method as claimed in Claim 52 wherein the surgery is gastrointestinal surgery or orthopedic surgery.

54 (currently amended). A The method as claimed in Claim 34 wherein the thrombin inhibitor is melagatran.

*C1
Conclusion*
55 (currently amended). A The method according to Claim 34 wherein the thrombin inhibitor is melagatran, and the prodrug is of formula



wherein R^1 represents linear or branched C_{1-6} alkyl and the OH group replaces one of the amino hydrogens in Pab.

56 (currently amended). A The method as claimed in Claim 55, wherein R^1 represents methyl, ethyl or propyl.

57 (currently amended). A The method as claimed in Claim 55, wherein R^1 represents ethyl.